Around 47 minutes into the Monday CC. He also mentioned engaging with the AD advocacy community, which was nice to hear. (On Friday I'd asked IR if the company would be doing that, so was glad to hear this.)
Given the estimated cost of Lecanemab, what do you expect would be the Anavex Life Sciences yearly revenue, if Anavex's Blarcamesine were FDA approved andcost each recipient just half the minimum yearly cost of $9,249 for lecanemab?
Based on an (internal) initial economic assessment, Eisai said that its annual “value-based price” of lecanemab would be anywhere between $9,249 and $35,605.
News 
Market Data 
Discover 
AI
